FinanceAsianet Newsable
CAPR stock falls on FDA approval doubts
in5points
CAPR stock is on track for its worst month in nine years amid FDA approval doubts.
Martin Shkreli has increased his criticism, piling on negative sentiment.
Retail investors have turned more bullish than ever despite the declines.
Analysts from Roth, B. Riley and Cantor have flagged elevated approval risk.
Multiple Wall Street firms have turned more cautious on the stock.
Story angle
Center-right
L
CL
C
CR
R
Mostly straight facts, with a light government- or market-friendly tilt.
About how the story is framed, not whether the facts are true.
Asianet Newsable
Center-right
Mixed factuality
Who owns this?
Asianet News Network
Rajeev Chandrasekhar / Jupiter Capital interests historically